Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

NCT01969838 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

432

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis

Interventions

DRUG: Momelotinib
DRUG: Ruxolitinib
DRUG: Placebo to match momelotinib
DRUG: Placebo to match ruxolitinib

Sponsor

Sierra Oncology LLC - a GSK company